Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

GW Pharma

EISAI

Eisai’s epilepsy drug Zonegran wins Swiss approval

Swissmedic licences new monotherapy indication for the treatment

- PMLiVE

Almirall launches Sativex in Italy

Brings cannabis-based drug for multiple sclerosis spasticity to market

- PMLiVE

European Commission hails progress on paediatric medicines

Says improvements made on both safety and research in Europe

- PMLiVE

Eisai pulls epilepsy drug Fycompa in Germany

Based on unfavourable assessment by pricing body

EU flag

Nine pharma firms face EU fines over pay-for-delay deals

Lundbeck could be the hardest hit with a maximum penalty of €240m

- PMLiVE

GSK/ Valeant’s Trobalt set for EU restrictions

Eye concerns prompt CHMP to recommend last-line use for the epilepsy drug

- PMLiVE

Gilead launches combination HIV pill in UK and Germany

Stribild is approved in EU as once-daily single tablet

- PMLiVE

Sanofi invests €20m in Morocco

Will also collaborate with government on diabetes, mental health, epilepsy and pharma training

- PMLiVE

GW Pharma says German Sativex pricing “unacceptable”

May pull MS drug from market

- PMLiVE

Will opportunity knock for eHealth in 2013?

If EC plans succeed, they will transform the way technology is used

- PMLiVE

New EC anti-smoking plans include ban on flavoured tobacco

Pictorial health warnings on cigarettes and regulation for e-cigarettes also proposed

- PMLiVE

EC appoints group to examine biotech patent laws

Will examine role of patents in genetic engineering

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links